Today’s AI Top Pick: TMDX

TransMedics (TMDX) is the cleanest intersection of strong fundamentals, confirming multi-timeframe tape, and a fresh positive catalyst — without being extended. On fundamentals it hits every leg of the screen with room to spare: PE 15.57 / fwdPe 19.59, ROE 45.22%, profit margin 27.04%, sales growth 30.24% YoY, EPS next-year growth 75.14%, analyst recom 1.58, and 75.5% average target upside. Shares are down -47.85% on the year and -44.23% YTD, so we are buying a demonstrably shorted (23.02% float) but genuinely profitable turnaround, not a story stock. The tape confirms rather than contradicts. Mid- and long-horizon forecasts are positive on ALL FOUR timeframes: 1h fc_mid +22.21% / fc_long +45.11%; 4h fc_mid +85.49% / fc_long +98.33%; 1d fc_mid +70.31% / fc_long +43.11%; 1wk fc_mid +30.24% / fc_long +32.80%. Bullish probability is 0.80 and near-term bullish is 0.60. Critically, we are NOT chasing: daily position_in_21bar_range is only 11.56%, weekly is 5.67%, and drawdown from daily 21-bar high is -13.89%. That is textbook 'basing after a washout,' not a breakout to fade. The news catalyst seals it: on 2026-07-01 TD Cowen reiterated Buy with a $120 PT (vs. $67.85 spot ≈ +77% upside) and a Stocktwits piece flagged the same 77% analyst-implied upside. There are no dilution, guidance-cut, or short-report headlines to worry about — the only cautionary note is a SeekingAlpha piece flagging margin recovery risk, which is a known thesis point already priced into the -47% drawdown. Why today and not wait? The 1h forecast is mildly negative (-3.68% fc_short) and 4h fc_short is +1.34%, so this is not an explosive-breakout entry — it's a base entry. That is exactly the setup you don't need to chase. Compare to PSIX (weekly fc_long -62.92% — a huge red flag despite great fundamentals) and CELH (100% position-in-range on three timeframes, plus 'fully priced' headlines). TMDX offers the best fundamentals-plus-forecast alignment with the least chase risk in the pool.